Yexiang Sun

Yexiang Sun

Auto-generated profile, based on publicly available information

Yexiang Sun

Department of Chronic Diseases and Health Promotion, Yinzhou District Centre for Disease Control and Prevention , Ningbo

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2025 in International Journal of Epidemiology
Verified
Journal Article
Closed access
JIANBING WangJIANBING Wang
JIANBING Wang
LYLuhua Yu
Luhua Yu
ZYZongming Yang
Zongming Yang
PSPeng Shen
Peng Shen
YSYexiang Sun
Yexiang Sun
LMLeonardo Martinez
Leonardo Martinez
Background: Although smoking is considered the primary cause of chronic obstructive pulmonary disease (COPD), there is a growing realization that there may be important secondary risk factors. Tuberculosis may lead to lung impairment; however, whether residual lung damage results in clinically significant, long-term outcomes, independent of smoking, has not been well studied. We aimed to investigate the association between tuberculosis and the subsequent development of COPD using a large, population-based cohort study. Methods: We conducted a longitudinal cohort study within the Chinese Electronic Health Records Research in Yinzhou study between 2009 and 2021. We followed participants free of COPD at the beginning of the study, and investigated whether previous or current tuberculosis was an important risk factor. Tuberculosis was recorded based on the Chinese National Disease Reporting system which includes all diagnosed cases at the city, provincial and national levels. We assessed the relationship between tuberculosis and COPD using multivariable survival models, adjusting for demographic and lifestyle characteristics, education level, comorbidities and use of medications. Results: Among 477 046 participants, 198 882 were eligible for inclusion in our analysis. In a multivariable model, pulmonary tuberculosis and all tuberculosis were associated with a 2.57-fold [95% confidence interval (CI), 2.31–2.87)] and 1.67-fold (95% CI, 1.48–1.90) increased COPD risk, respectively. Stronger associations of pulmonary tuberculosis and all tuberculosis with COPD were seen in participants who were elderly, or with lower body mass index or education level (Pinteraction<0.001). People with tuberculosis were at an increased risk of COPD if they were current smokers [adjusted hazard ratio (aHR), 1.40; 95% CI, 1.02–1.93] or non-smokers (aHR, 1.72; 95% CI, 1.50–1.98). Conclusions: Persons who developed tuberculosis were at much greater risk of developing COPD, even accounting for smoking and other potential confounders.

21 August 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
XGXIN GAO
XIN GAO
YSYexiang Sun
Yexiang Sun
PSPeng Shen
Peng Shen
JGJinxin Guo
Jinxin Guo
YCYunpeng Chen
Yunpeng Chen
SZSiyan Zhan
Siyan Zhan
Background: In China, the 2022–2023 influenza season began earlier and was characterized by higher levels of influenza activity and co-circulation of various respiratory pathogens compared with seasons before the coronavirus disease 2019 (COVID-19) pandemic. Timely and precise estimates of influenza vaccine effectiveness (IVE) against infections can be used to guide public health measures. Methods: A test-negative study was conducted to estimate IVE against laboratory-confirmed influenza using data from the CHinese Electronic health Records Research in Yinzhou (CHERRY) study that prospectively integrated laboratory, vaccination, and health administrative data in Yinzhou, southern China. We included patients who presented influenza-like illness and received nucleic acid tests and/or antigen tests between October 2023 and March 2024. Estimates of IVE were adjusted for age, gender, month of specimen submitted, chronic comorbidities, and hospitalization status. Results: A total of 205 028 participants, including 96 298 influenza cases (7.6% vaccinated) and 108 730 influenza-negative controls (13.4% vaccinated), were eligible for this analysis. The estimates of IVE were 49.4% (95% CI, 47.8%–50.9%), 41.9% (95% CI, 39.8%–44.0%), and 59.9% (95% CI, 57.9%–61.9%) against overall influenza, influenza A, and influenza B, respectively. A lower IVE was observed for individuals aged 7–17 years (38.6%), vs 45.8% for 6 months–6 years, 46.7% for 18–64 years, and 46.1% for ≥65 years. Vaccination reduced the risk of infection by 44.4% among patients with chronic comorbidities. IVEs varied by epidemic weeks with the changes in influenza activity levels and the switch of dominant influenza strains. Conclusions: Influenza vaccination in the 2023–2024 season was protective against infection for the entire population.

17 April 2025 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
ZFZhangping Fu
Zhangping Fu
PSPeng Shen
Peng Shen
JLJingyuan Liang
Jingyuan Liang
XLXiaofei Liu
Xiaofei Liu
YSYexiang Sun
Yexiang Sun
PGPei Gao
Pei Gao
Aims: The updated 2023 European Guideline recommended SCORE2-Diabetes to estimate cardiovascular disease (CVD) risk in patients with diabetes; however, external validation is lacking. The study aims to validate SCORE2-Diabetes in Chinese and assess its broader applicability and adaptability across diverse settings. Methods and results: This study included patients with diabetes aged 40–90 without prior CVD from a population-based Chinese cohort. Ten-year CVD risk was calculated using the original and recalibrated SCORE2-Diabetes, where four sets of scaling factors for different risk regions were provided. The outcome was defined consistently with SCORE2-Diabetes. During a median follow-up of 7.09 years, 50 426 Chinese patients experienced 6540 CVD events and 2852 non-CVD deaths. The C-statistic of the SCORE2-Diabetes was 0.702 (95% confidence interval: 0.691–0.713) in men and 0.726 (0.716–0.736) in women. The original SCORE2-Diabetes underestimated risk by 30% in men and 50% in women, whereas the recalibrated SCORE2-Diabetes using high-risk region scaling factor had the best calibration, overestimating risk by only 4% in men and underestimating by 7% in women. Of the patients, 14 501 (28.76%) and 20 789(41.23%) were classified as very high (≥20%) and high (10–20%) risk categories, respectively. The significant difference between average baseline and targeted LDL-C was observed in the very high-risk group (2.85 vs. 1.40 mmol/L). Conclusion: With the appropriate selection of the scaling factor, SCORE2-Diabetes shows satisfactory discrimination and calibration in Chinese, indicating its good generalizability. According to the latest guideline, the risk assessment in this real-world population indicated a significant demand for medications with cardiovascular efficacy and a substantial burden for lipid management.